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Prevention of Cardiovascular Events in Variant Angina by Long-Term
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Stanford. California
In 43 patients with variant angina, the cardiovascular
event rate during diltiazem therapy was compared with
that in an equal time period before initiation of therapy.
Cardiovascular events, that is, myocardial infarction,
sudden death and hospitalization for prolonged angina,
were decreased significantly (p < 0.01) during the initial
6 months and mean 19.6 months of therapy. Based on
the binomial principle, there were 22 events during the
The introduction of calcium antagonist therapy for patients
with variant angina has resulted in excellent short-term re-
sults, with significant reductions in angina frequency and
nitroglycerin consumption (1-3). Whether these short-term
findings can be maintained over longer periods of time and
whether these agents can reduce the complication rate in
patients with coronary artery spasm has not been clarified.
We therefore reviewed the course of the first 43 patients
who have taken diltiazem regularly during a mean 19.6
months of follow-up in the Coronary Artery Spasm Clinic
at Stanford University Medical Center. We analyzed both
the angina frequency and cardiovascular event rate in an
equal time period before the initiation of diltiazem therapy
and compared these during a similar time period on chronic
drug therapy,
Methods
Study patients. Coronary artery spasm was documented
in the 43 patients by either electrocardiographic or angio-
graphic criteria. Electrocardiographic criteria required spon-
taneous (26 patients) or ergonovine maleate-induced (17
patients) transient ST segment elevation of 0.1 mV or more
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mean 19.6 months before therapy and 2 events during
the equal time period on therapy. Nopatient died during
follow-up. The frequency of angina was decreased by
94%. Diltiazem was well tolerated by all patients and
no patient had to discontinue therapy because of adverse
effects. It is concluded that long-term diltiazem therapy
reduces cardiovascular events in patients with variant
angina.
above the baseline during the patient's typical episode of
angina pectoris. Angiographic criteria required that chest
pain be associated with either spontaneous or ergonovine
maleate-induced focal coronary spasm that reduced vessel
diameter by 50% or more compared with the pain-free state.
Of the 43 patients who had been referred to the Coronary
Artery Spasm Clinic at Stanford for medically refractory
angina, 38% had a 6 month to 8 year history of angina that
had been partially responsive to standard antianginal ther-
apy, such as short- and long-term acting nitrates, beta-
adrenergic blocking agents and, in some instances, alpha-
adrenergic blocking agents, All study patients had typical
angina pectoris that occurred at rest and was responsive to
sublingual nitroglycerin. Twenty-six patients had stress-
induced angina as well.
Treatment protocol. After informed consent for use of
an investigational drug was obtained, patients were started
on treatment with diltiazem, 60 mg orally every 6 hours.
If the patients continued to have pain, the dose was increased
to 90 mg every 6 hours. Patients were initially evaluated at
2 week intervals and subsequently at not less than 8 week
intervals for the duration of the follow-up period. Every
effort was made to obtain a pain-free state in these patients,
and isosorbide dinitrate was added if angina persisted on
diltiazem therapy, Patients were followed up for a mean of
19.6 months (range 6 to 28.5).
Patient characteristics. This long-term follow-up group
of patients consisted of 43 subjects, 19 men and 24 women,
with a mean age of 52 years (range 28 to 71), Angina at
rest was reported by all patients for a mean of 51 months
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(range 1 week to 234 months) before initiation of diltiazem
therapy. In addition, 16 patients (37.2%) reported angina
on exertion. Angina frequency was reported as a mean 23
attacks/week (range 1 to 105) in the 4 weeks before initiation
of diltiazem therapy.
Coronary angiographic findings (Table 1). Six pa-
tients had 70% or greater occlusion of one or more major
coronary arteries, and one of these patients had had prior
coronary bypass surgery to the left anterior descending coro-
nary artery. A second patient had undergone percutaneous
angioplasty of the proximal left anterior descending coro-
nary artery. Twenty-five patients (53.5%) had coronary oc-
clusive lesions ranging from 20 to 60% and 13 patients had
coronary occlusive lesions of less than 20%. Table 1 shows
the location of focal spasm occurring either during ergo-
novine maleate-induced or spontaneous coronary artery spasm.
Thirty-eight patients had spasm involving one vessel and
five patients involving two vessels. Spasm of the left anterior
descending coronary artery occurred in 21 patients, of the
right coronary artery in 25 patients and of the circumflex
artery in 2 patients.
Statistical analysis. Cardiovascular events were defined
as 1) sudden cardiac death (with or without subsequent
resuscitation) occurring less than 1 hour after onset of symp-
toms; 2) myocardial infarction with development of new Q
waves compared with prior electrocardiograms or serum
creatine kinase (CK) increase of at least 200 IV with an
abnormally high MB fraction; and 3) hospitalization to rule
out a myocardial infarction because of prolonged angina
pectoris. These events were then analyzed in the 6 months
before and 6 months after initiation of diltiazem therapy in
the entire patient group. Additionally, the cardiovascular
events during the entire diltiazem therapy period (mean 19.6
months) were compared with those in an equal time period
before therapy (mean 19.6 months).
Analysis was performed utilizing the sign test based on
binomial distribution (Ho:p = 112) (4). All event data were
gathered from medical records and private physician referral
information. Ifa patient had two hospitalizations to rule out
a myocardial infarction and one episode of cardiovascular
collapse due to ventricular fibrillation, this was counted as
only one event. If one event occurred before therapy and
one event occurred during therapy, by the binomial principle
no change in event rate occurred.
Results
Angina frequency. We previously reported on the effect
of long-term diltiazem therapy on angina frequency in a
subgroup of 36 of the 43 patients in this study (5). The
angina frequency for these 43 patients was reduced from a
mean of 21.5 attacks/week before therapy to a mean of 1.3
attacks/week during a mean 19.6 months of follow-up. This
94% overall reduction in angina frequency was accom-
plished with a mean dose of 270 mg of diltiazem daily.
Isosorbide dinitrate was used concurrently with diltiazem in
14 of the 43 patients. Of 41 patients receiving 240 mg/day
of diltiazem, 21 (51.2%) were pain-free and another 5 pa-
tients became pain-free with the addition of isosorbide din-
itrate. A total of 25 patients were advanced to a higher dose
of diltiazem (360 mg/day) in an effort to completely prevent
angina. Of these patients, 10 reported a pain-free state and
15 (60%) excellent relief of pain. Twenty-two patients did
not have complete relief of pain on either 240 or 360 mg/
day dosage. In these patients, pain breakthrough occurred
a mean of 1.7 times during the 19.6 months of follow-up.
These breakthroughs of angina tended to occur during times
of increased emotional stress and to resolve spontaneously
without significant changes in medication dosage. Seven of
these 22 patients had otherwise been pain-free during their
entire follow-up period. Two patients did require hospital-
ization during the breakthrough period and will be discussed
in more detail later.
Prior cardiovascular events. The patients had a wide
range of cardiovascular events during the specified 6 or mean
19.6 month time periods before initiation of diltiazem ther-
apy. These events included myocardial infarction in 5 pa-
tients, sudden death in 4 patients (who were resuscitated)
and one or more hospitalizations to rule out myocardial
infarction in 30 patients. In addition, 22 of the 43 patients
had one or more documented episodes of ventricular tachy-
cardia or atrioventricular block.
New cardiovascular events. A significant decrease in
cardiovascular event rate occurred during the 6 and mean
19.6 month diltiazem therapy periods (probability [p] <
0.01). During long-term diltiazem therapy, there were 2
new events compared with 22 events before therapy (Fig.
1). One patient (Case 18) who had a 70% occlusion of the
right coronary artery with superimposed focal spasm was
hospitalized for an uneventful inferior myocardial infarc-
tion. Another patient (Case 17) with both right and left
coronary spasm was hospitalized to rule out a myocardial
infarction. Both patients had their events while receiving
240 mg/day diltiazem. No patient died during follow-up.
Cardiovascular events before and during diltiazem ther-
apy were compared on the basis of extent of occlusive coro-
nary artery disease (Table 2). There were no new events
during therapy in the 20 patients with 20% or less coronary
stenosis. This compared with 24 events before therapy. Two
new events during therapy, compared with 19 events before
therapy, occurred in 17 patients with 21 to 69% stenosis in
one or more arteries. In the six patients with over 70%
stenosis, there were two events during therapy compared
with nine events before diltiazem therapy.
Adverse drug effects. Although side effects were no-
tably absent, six patients complained of minimal to mild
pedal edema. In two of these patients, administration of
diuretic drugs was instituted with good results. No diuretic
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Table 1. Pat ient Characteristics Before St udy
% Coronary Stenosis Episodes
Age (yr)/ Symptoms Effort of Anginal
Case Sex (mo) Angina TM CV Event RCA LAD LCx Week
52F 68 No Neg RO Ml x 3. 20" 0 0 ~ 5
syncope
2 47F 63 No Neg RO Ml x 6. 40 40* 0 35
syncope
3 56M 51 No Neg RO MI x 2 60" 30 30 30
4 46M 32 No Neg MI x I. 20'" 20 0 5
ROMI x
5 57M 234 No Neg RO MI x 4 O~ 0 0 12
6 54M 120 No Neg RO MI x I 30" 0 0 I
7 51M 146 Yes Neg None 0" 20 0 25
8 60M 12 Yes RO MI x 2 50 50" 0 7
9 51F 6 No Neg None 0" 0 0 28
10 58F 8 No Pos RO MI x 2 0 70i 0 28
I I 53F 10 No Neg RO MI x I 25" 50 0 40
12 50F 3 No Pos RO MI x I 0 50' 0 4
13 54F 40 Yes Neg None 20 (V 50 36
14 48F 7 Yes Neg None 0 0* 0 6
15 54F II Ye, SO x I. 0' 0 0 30
RO MI x 4
16 49F 2 No Neg Ml x 1 (sub) 60 50" a 14
17 43F 36 No Pos (ST t ) SO x I. 50' 75" 0 4
CABG x I.
RO MI x 2
18 5 IF 174 Ye, Neg None 70' 0 0 30
19 33F 22 No SO x I a 0" or 14
20 40F 36 Yes Neg None 0 0' 0 21
21 71M 46 No RO MI x 2 30' 30' 25 7
(VT)
22 49M 156 No Neg RO MI x 3 0' 0 0
(VT. CHB)
23 54F 40 No RO Ml x I. 30'" 30 20 10
pacemaker
24 42M 24 No Neg RO MI x I 20' 30 0 6
25 67F 7 No RO MI x I. O' 0 0 21
pacemaker
26 44F 48 Ye, Neg None 50" 15 25 3
27 59M 16 Yes Pos Angioplasty 0 30' 0 3
x 1
28 55F 10 No RO MI x I 20" 20 0 5
29 28M 4 No Neg MI x 1 20" 0 0 20
30 5 1M 32 Yes Neg None 0 0" 0 85
31 49M ltwk) No (VT) 50T 0 0 21
RO MI x
32 49F 66 No Neg RO MI x 2 20 O T 0" 3
33 46F 5 Yes None 0 50* 0 105
34 51F 39 No Neg MI x 2 0' 0* 0 21
35 40F 2(wk) No Pos MI x I. 0 70* 0 3
SO x I.
RO Ml x 2
36 54F 36 No None 0'" 0* 0 50
37 6 1M 180 Yes Pos (ST t rec) None 50' 0 0 5
38 5 1M 96 Yes None 30' 0 80 56
39 38M 17 Yes Pos (ST t rec) None 60* 30 30 10
40 58M 5 Yes None 15 20" 0 100
4 1 52F 48 Yes Pos None 0 0* 0 3
42 47M 24 No None 0* 0 0 3
43 56M 106 No Pos (ST t rec) None 20* 20 90 21
*Indicates artery with spasm.
CABG = coronary artery bypass graft surgery; CHB = complete heart block; CV = cardiovascular; LAD = left anterior descending coronary
artery; LCx = left circumflex coronary artery; Neg = negative; Pos = positive; RCA = right coronary artery; rec = recovery; RO MI = rule out
myocardial Infarction; SO = sudden death; ST t = ST segment elevation; sub > subendocardial, TM = treadmill test: VT = ventricular tachycardia.
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Figure 1. Total cardiovascular events (myo-
cardial infarction, sudden death or hospital-
ization to rule out myocardial infarction) in 43
patients with documented coronary spasm.
Events are noted for the 6 months immediately
before and after initiation of diltiazem therapy,
as well as during the mean 19.6 months before
and after initiation of diltiazem therapy.
mean 19.6 months mean 19.6 months
therapy was required in the other four patients. There were
no reports of headache, hypotension or heart block, and
patients routinely reported that they felt better while on
treatment. No patients had to stop diltiazem therapy because
of adverse side effects.
Discussion
Diltiazem is the newest of a group of diverse chemical
agents called calcium influx blocking drugs. These agents
act by inhibiting sarcolemmal calcium flux during the pla-
teau phase of the action potential. This action results in the
physiologic relaxation of coronary vessel smooth muscle as
well as the inhibition of spasm in areas of coronary arteries
that develop focal pharmacologic supersensitivity (6). Dil-
tiazem appears to be relatively selective for the coronary
vasculature, exhibits minimal or negative inotropic effect
and minimally decreases systemic vascular resistance (7).
Effect on angina frequency. As previously reported,
the remarkable decrease in angina frequency in this patient
group was encouraging because the majority of these pa-
tients had been referred to our coronary artery spasm clinic
for medically refractory angina pectoris. Coronary spasm
was documented in all patients and all 43 patients reported
that their angina responded to sublingual nitroglycerin. These
unblinded observations are consistent with both short-term
Table 2. Comparison of Total Cardiovascular Events Before
and During Diltiazem Therapy by Severity of Occlusive
Coronary Artery Disease
Degree of Occlusive Disease
Cardio-
s 20% 211069% ~ 70%
vascular
(n = 20) (n = 17) (n = 6)
Event Before During Before During Before Dunng
RO MI 18 0 18 2 6 I
MI 4 0 1 0 I 1
SD 2 0 0 0 2 0
Total 24 0 19 2 9 2
MI = myocardial infarction; n = number of patients: RO = rule out;
SD = sudden death.
studies by Rosenthal et al. (1) and Pepine et al. (8), both
of whom described 50 to 100% resolution of angina episodes
in patients taking 240 mg/day of diltiazem during a 10 week
double-blind, placebo-controlled study. We recently re-
ported a 44 week double-blind study of diltiazem versus
placebo that included a paired placebo during one of five
28 day cycles during the first period and a similar 28 day
placebo period during the last six 28 day cycles (9). In that
study, a 73% decrease in angina frequency occurred during
phase I and an 80% decrease occurred during phase II.
Attenuation of disease activity was also observed with an
approximate 50% reduction in angina frequency during the
placebo phase of phase II compared with the placebo phase
of phase I.
The only other long-term study of calcium-blocking agents
was by Johnson et al. (3), who carried out a 9 month double-
blind, randomized trial in 18 patients who received either
placebo or verapamil plus isosorbide dinitrate. They noted
an 86% reduction in pain frequency and an 85% reduction
in nitroglycerin consumption compared with placebo pe-
riods. Sequential Holter monitoring also documented a 77%
reduction in ST segment deviation, which correlated quite
well with subjective reports of pain relief.
It therefore appears that the long-term efficacy of 94%
reduction of angina episodes in our current open label study
is similar to that reported in previous, more controlled,
double-blind studies (1,8,10). The similar reduction in pain
frequency in these long-term studies suggests that these
calcium antagonists are quite similar in their efficacy for
prophylaxis of angina episodes in variant angina.
Effect on cardiovascular events. The reduction in car-
diovascular events from 22 during the mean 19.6 month
period before the initiation of therapy to 2 events during the
matched mean 19.6 months during diltiazem therapy was
quite similar to the reduction in angina frequency. There
was a tendency for more new events to occur in patients
with higher degrees of occlusive coronary disease. These
observations suggest that many of the cardiovascular events
reported in this patient group are directly related to repeated
episodes of coronary artery spasm producing myocardial
ischemia and serious ventricular arrhythmias or myocardial
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infarction. We have observed that ventricular arrhythmias
in this patient group almost invariably develop during ep-
isodes of ST segment shift and are therefore related to coro-
nary artery spasm. Thus, it is not surprising that diltiazem
would reduce the cardiovascular event rate by reducing an-
gina frequency.
Comparison with previous studies. One limitation of
this study is its retrospective longitudinal nature. The natural
history of variant angina has been difficult to determine and
the disease course is known to be highly variable, with some
patients becoming completely pain-free on placebo and other
patients reporting recurrent exacerbations on therapy. De-
spite these limitations and the variable nature of variant
angina, previous reports suggest that our event rate during
diltiazem therapy is quite low. Severi et al. (11) reported
on 138 patients with variant angina who were followed up
for 2 to 8 years after identification of coronary spasm as the
cause of their angina. All their patients had a history of
angina at rest while 42% reported effort-related angina.
Patients were treated with a wide variety of nitrates and
calcium antagonists, primarily verapamil. They reported that
of the 120 patients who were treated medically, 7 died and
4 had acute myocardial infarction. In addition, at the end
of the 4 year period, 50% of patients were asymptomatic
for at least 12 months. These authors commented that new
cardiovascular events, that is, death or myocardial infarc-
tion, tended to occur in patients with more severe underlying
coronary atherosclerosis. Although one of our patients who
had a 70% lesion of the right coronary artery had a sub-
sequent myocardial infarction, we also observed patients
with similar degrees of occlusive coronary disease who had
no new cardiovascular events.
Waters et al. (12) recently reported on the posthospital
course of 114 patients with variant angina who were fol-
lowed up for a mean period of 26 months. Six of their
patients died suddenly and another 13 were resuscitated from
sudden cardiac death. The extent of coronary disease and
prevalence of left ventricular dysfunction in these 19patients
were similar to those of survivors. The prevalence of serious
arrhythmias during episodes of chest pain was greater in the
19 victims of sudden death than in survivors, and these
patients tended to have higher degrees of ST segment ele-
vation during chest pain, perhaps suggesting more severe
transmural myocardial ischemia which resulted in arrhyth-
mias. During the follow-up period, nifedipine, diltiazem
and verapamil all became available for use in this patient
group; however, only six patients were on calcium antag-
onist therapy at the time of death and only one patient was
receiving diltiazem. It is also of interest that 8 of those 19
patients who died suddenly or were resuscitated from sudden
death were free of angina during the preceding month, sug-
gesting that this patient group also was subject to relatively
sudden changes in angina frequency.
Side effects. If the observed cardiovascular event rate
before initiation of diltiazem therapy in our patients reflects
the actual morbidity of variant angina due to coronary spasm,
it would appear that long-term calcium-blocking therapy
with an agent such as diltiazem would be of great impor-
tance. The lack of significant side effects noted in our patient
group correlates with the excellent compliance of patients
in our clinic. Furthermore, the fact that no patient had to
stop therapy because of an adverse drug reaction documents
its excellent tolerance by our patient group.
Conclusion. We have analyzed the cardiovascular event
rate in 43 patients with variant angina before and during
diltiazem therapy. The 92% reduction in new cardiovascular
events in patients receiving diltiazem closely correlates with
a 94% reduction in overall angina frequency. We conclude
that long-term diltiazem therapy is highly effective in pre-
venting new cardiovascular events and does not appear to
be associated with pharmacologic tolerance or significant
adverse effects in patients with angina due to coronary artery
spasm.
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